Eikon Therapeutics (EIKN) FDA Approvals

$5.30 +0.15 (+2.82%)
As of 12:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Upcoming FDA Events for Eikon Therapeutics

Eikon Therapeutics (EIKN) has upcoming FDA regulatory milestones for EIK1006. The table below outlines estimated target dates and event types for these pending regulatory actions.

DrugTarget DateAnnouncement
EIK1006H2 2027Initial Data
Eikon Therapeutics, Inc. announced that Initial clinical data from Phase 1/2 study expected in second half of 2027 (November 17, 2026)

Eikon Therapeutics' Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Eikon Therapeutics (EIKN). Over the past two years, Eikon Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as EIK1006 and EIK1001. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

EIK1006 FDA Regulatory Events

EIK1006 is a drug developed by Eikon Therapeutics for the following indication: in Advanced Metastatic Prostate Cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

EIK1001 FDA Regulatory Timeline and Events

EIK1001 is a drug developed by Eikon Therapeutics for the following indication: patients with stage IV NSCLC. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Eikon Therapeutics FDA Events - Frequently Asked Questions

In the past two years, Eikon Therapeutics (EIKN) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, Eikon Therapeutics (EIKN) has reported FDA regulatory activity for the following drugs: EIK1001 and EIK1006.

The most recent FDA-related event for Eikon Therapeutics occurred on November 17, 2026, involving EIK1006. The update was categorized as "FDA Clearance," with the company reporting: "ikon Therapeutics, announced U.S. Food and Drug Administration clearance to proceed for the Investigational New Drug (IND) application to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. Inc."

Current therapies from Eikon Therapeutics in review with the FDA target conditions such as:

  • patients with stage IV NSCLC - EIK1001
  • in Advanced Metastatic Prostate Cancer - EIK1006
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:EIKN last updated on 11/17/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners